1. Scrip
  2. >>Business
  3. >>Strategy

Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth

 
• By Jessica Merrill

With a new name and focused strategy, Pfizer’s Essential Health business has evolved since the acquisition of Hospira in 2015. Group President John Young outlined the company’s plans to transition a unit that was established to manage patent expirations to become a growth center.

Pfizer Inc. has a goal to turn its Essential Health business unit – originally established to help the company manage the loss of exclusivity of Lipitor and other blockbuster drugs – into a growth driver. Group President John Young and other top executives outlined the strategy to get there during a media briefing at the company’s headquarters in New York Nov. 10.

Essential Health has a lower profile than Pfizer’s other business unit, Innovative Health, under which the company develops and markets...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.